Barts Health NHS Trust


Klinik

Standort der Organisation:
London, Großbritannien (UK)


Publikationen in Kooperation mit FAU-Wissenschaftern


Fox, K., Achenbach, S., Bax, J., Cosyns, B., Delgado, V., Dweck, M.R.,... Popescu, B.A. (2019). Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging. European Heart Journal, 40(6), 553-558. https://dx.doi.org/10.1093/eurheartj/ehy669
Bertog, S.C., Sobotka, N.A., Sobotka, P.A., Lobo, M.D., Sievert, K., Vaskelyte, L.,... Schmieder, R. (2018). Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Current Hypertension Reports, 20(3). https://dx.doi.org/10.1007/s11906-018-0816-8
Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2018). Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial.
Siegel, C.A., Lichtenstein, G., Siegmund, B., Lewis, J.D., Wolf, D., Louis, E.,... Dolin, P. (2017). Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02). (pp. S333-S334).
Townsend, R.R., Mahfoud, F., Kandzari, D.E., Kario, K., Pocock, S., Weber, M.A.,... Böhm, M. (2017). Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. https://dx.doi.org/10.1016/S0140-6736(17)32281-X
Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C.,... Ramus, S.J. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 3(12). https://dx.doi.org/10.1001/jamaoncol.2017.3290
Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2017). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL. (pp. 952-953).
Hall, S., Mease, P., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J.,... Mpofu, S. (2017). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. (pp. 37-38).
Kavanaugh, A., Mease, P., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2016). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1. (pp. 598-598).
Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2016). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial.
Nieman, K., Achenbach, S., Pugliese, F., Cosyns, B., Lancellotti, P., & Kitsiou, A. (2015). Cardiac computed tomography core syllabus of the European Association of Cardiovascular Imaging (EACVI). European Heart Journal Cardiovascular Imaging, 16(4), 351-2. https://dx.doi.org/10.1093/ehjci/jeu298

Zuletzt aktualisiert 2017-20-06 um 07:38